Introducing BeatsX: New Premium Wireless, Bluetooth Earphones from Beats by Dr. Dre
Beats by Dr. Dre (Beats) today announced a host of exceptional new wireless products, expanding the brand’s premium portfolio to include a new line of wireless earphones called BeatsX along with the next generation of two current best-sellers with the introduction of Powerbeats3 Wireless earphones and Beats Solo3 Wireless headphones. As a collection, these new products include the Apple W1 chip, Class 1 Bluetooth, Fast Fuel charge and the premium sound fans around the world have come to expect from Beats products. Beats was co-founded by Dr. Dre and Jimmy Iovine and is part of Apple.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160907006808/en/
Beats by Dr. Dre's new collection of wireless products boasts integrated Apple W1 chip, Class 1 Bluetooth, extended battery life, Fast Fuel charge, and the premium sound experience that is now synonymous with Beats. (Graphic: Business Wire)
"Beats has always been dedicated to delivering the best possible music listening experience,” said Beats President Luke Wood. “Now that almost everything we consume in media has a sound component, superior audio playback quality is key. With our new product, we are delivering great design, innovation and sound so that you can hear everything the way the content creators imagined.”
BeatsX is an entirely new line of earphones, expertly designed to accommodate sophisticated audio advancements within its small form factor. Its simplistic, fluid design keeps BeatsX extremely light and nearly unnoticeable while wearing. Compatible with both iOS and Android devices, BeatsX features Class 1 Bluetooth for optimal connectivity. For iOS10 users, the Apple W1 chip provides an easy one-step Bluetooth connection and the added ability to toggle seamlessly between iCloud-registered devices. BeatsX sets a new standard for battery efficiency with Fast Fuel, which provides 2 hours of playback after just 5 minutes of charging and up to 8 hours after just 45 minutes of charging via the included Lightning cable. The RemoteTalk allows you to take calls, play music and activate Siri. The Flex-Form cable and variety of eartip and removable wingtip options provide a flexible, secure and comfortable fit during use. When you’re not using the earphones, magnetic ear buds keep them tangle-free around your neck, and they easily coil to fit into a compact carrying case for storage and portability.
Powerbeats 3 Wireless
Powerbeats3 Wireless truly takes one of the world’s best-selling wireless earphones to the next level. Improved ergonomics provide a better fit and sound experience, while Fast Fuel provides 1 hour of playback after just 5 minutes of charging via the included micro-USB cable. When fully charged, these sweat and water resistant earphones offer up to a 12-hour extended battery life. Additionally, the new Powerbeats3 Wireless earphones include integrated Class 1 Bluetooth and RemoteTalk, which allows you to take calls, play music and activate Siri.
Beats Solo 3 Wireless
Beats Solo3 Wireless is the next evolution of the already iconic Solo line of on-ear headphones. This new product provides up to 40 hours of battery life due to the efficiency of the Apple W1 chip, as well as Class 1 Bluetooth. The earcup controls let you take calls, play music and activate Siri, and Fast Fuel provides 3 hours of playback after just 5 minutes of charging via the included micro-USB cable. Beats Solo3 Wireless stays true to its predecessor with the same award-winning sound and portable, durable design featuring a flexible headband, 360-degree pivoting ear cups and noise isolation.
Visit Apple.com for pricing and availability. Additional assets for Beats X , Powerbeats 3 Wireless and Solo 3 Wireless available upon request.
Beats by Dr. Dre (Beats) is a leading audio brand founded in 2006 by Dr. Dre and Jimmy Iovine. Through its family of premium consumer headphones, earphones and speakers, Beats has introduced an entirely new generation to the possibilities of premium sound entertainment. The brand’s continued success helps bring the energy, emotion and excitement of playback in the recording studio back to the listening experience for music lovers worldwide. Beats was acquired by Apple Inc. in July 2014.
Beats by Dr. Dre, Beats, Fast Fuel, Powerbeats, RemoteTalk and Solo are trademarks of Beats Electronics, LLC. Apple, Lightning and Siri are trademarks of Apple Inc. Other company and product names may be trademarks of their respective owners.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Seoul Semiconductor’s SunLike Series LEDs Win Product of the Year Award from Elektronik Magazine23.3.2018 18:28 | Pressemelding
Seoul Semiconductor, a global innovator of LED products and technology, announced on March 23rd that its SunLike Series natural spectrum LED product won the Gold Award at the Elektronik Product of the Year 2018 Awards, hosted by Elektronik (http://www.elektroniknet.de), a leading German electronics publication. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005646/en/ Product of the Year Award from Elektronik Magazine (SunLike) (Photo: Business Wire) As a publication specializing in electrical and electronic components, “Elektronik” is a prestigious magazine with an illustrious history and the largest number of subscribers in Germany. Over the past 20 years, they have conducted annual surveys among their subscribers to find the “most creative and innovative products.” Based on these survey results, Elektronik selects the top product that with the most impact in its corresponding field, and confers the awards accordingl
Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05 | Pressemelding
Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the
Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52 | Pressemelding
Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal
CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50 | Pressemelding
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation
Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46 | Pressemelding
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c
Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00 | Pressemelding
Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at www.aitheon.com/news) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180323005269/en/ Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on